Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Rosenthal

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Neuro-Oncology|November 18, 2021
Consensus core clinical data elements for meningiomas (v2021.1)Farshad Nassiri, Justin Z Wang, Karolyn Au, et al.
Neuro-Oncology|May 13, 2021
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU studyHao-Wen Sim, Kerrie L McDonald, Zarnie Lwin, et al.
The Lancet. Oncology|June 8, 2013
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trialIan F Tannock, Karim Fizazi, Sergey Ivanov, et al.
Neuro-Oncology|May 31, 2022
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trialMacarena I de la Fuente, Howard Colman, Mark Rosenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaTracy T Batchelor, Paul Mulholland, Bart Neyns, et al.
JNCI Cancer Spectrum|May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Neuro-Oncology|December 21, 2022
Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26Karen Alpen, Claire M Vajdic, Robert J MacInnis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Pediatric Pulmonology|July 28, 2023
Unsupervised home spirometry is not equivalent to supervised clinic spirometry in children and young people with cystic fibrosis: Results from the CLIMB-CF studyClaire Edmondson, Nicole Westrupp, Christopher Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate CancerSusan Halabi, William Kevin Kelly, Hua Ma, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Neuro-Oncology|November 18, 2021
Consensus core clinical data elements for meningiomas (v2021.1)Farshad Nassiri, Justin Z Wang, Karolyn Au, et al.
Neuro-Oncology|May 13, 2021
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU studyHao-Wen Sim, Kerrie L McDonald, Zarnie Lwin, et al.
The Lancet. Oncology|June 8, 2013
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trialIan F Tannock, Karim Fizazi, Sergey Ivanov, et al.
Neuro-Oncology|May 31, 2022
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trialMacarena I de la Fuente, Howard Colman, Mark Rosenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaTracy T Batchelor, Paul Mulholland, Bart Neyns, et al.
JNCI Cancer Spectrum|May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Neuro-Oncology|December 21, 2022
Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26Karen Alpen, Claire M Vajdic, Robert J MacInnis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Pediatric Pulmonology|July 28, 2023
Unsupervised home spirometry is not equivalent to supervised clinic spirometry in children and young people with cystic fibrosis: Results from the CLIMB-CF studyClaire Edmondson, Nicole Westrupp, Christopher Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate CancerSusan Halabi, William Kevin Kelly, Hua Ma, et al.
Pageof 11